PMDA drug package insert
セパミット−R細粒2％
PMDA Prescription drug · 日本ジェネリック株式会社 · package insert Feb 2, 2026
Key facts
| Brand names | セパミット−R細粒2％ |
|---|---|
| Nonproprietary names | ニフェジピン |
| Companies | 製造販売元／日本ジェネリック株式会社 |
| Product type | Prescription drug |
| Therapeutic category | カルシウム拮抗剤・ニフェジピン持効性製剤 |
| Therapeutic category codes | 872171 |
| YJ codes | 2171014C2032 |
| Approval numbers | 21900AMX01707000 |
| Package insert edition | 第6版 |
| Package insert date | Feb 2, 2026 |
| PMDA document key | 580591_2171014C2032_3 |
| PMDA company code | 580591 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: